|
1
|
Ghoncheh M, Pournamdar Z and Salehiniya H:
Incidence and mortality and epidemiology of breast cancer in the
world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Emens LA: Breast cancer immunotherapy:
Facts and hopes. Clin Cancer Res. 24:511–520. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saponaro C, Vagheggini A, Scarpi E,
Centonze M, Catacchio I, Popescu O, Pastena MI, Giotta F,
Silvestris N and Mangia A: NHERF1 and tumor microenvironment: A new
scene in invasive breast carcinoma. J Exp Clin Cancer Res.
37:962018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shiao SL, Ganesan AP, Rugo HS and Coussens
LM: Immune microenvironments in solid tumors: New targets for
therapy. Genes Dev. 25:2559–2572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Naito Y, Saito K, Shiiba K, Ohuchi A,
Saigenji K, Nagura H and Ohtani H: CD8+ T cells infiltrated within
cancer cell nests as a prognostic factor in human colorectal
cancer. Cancer Res. 58:3491–3494. 1998.PubMed/NCBI
|
|
7
|
Paijens ST, Vledder A, de Bruyn M and
Nijman HW: Tumor-infiltrating lymphocytes in the immunotherapy era.
Cell Mol Immunol. 18:842–859. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lotfinejad P, Asghari Jafarabadi M, Abdoli
Shadbad M, Kazemi T, Pashazadeh F, Sandoghchian Shotorbani S,
Jadidi Niaragh F, Baghbanzadeh A, Vahed N, Silvestris NJ and
Baradaran B: Prognostic role and clinical significance of
tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1
(PD-L1) expression in triple-negative breast cancer (TNBC): A
systematic review and meta-analysis study. Diagnostics (Basel).
10:7042020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Farhood B, Najafi M and Mortezaee K:
CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J
Cell Physiol. 234:8509–8521. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B,
Zhong R, Xiong S, Li J, Chen Z, et al: The association between CD8+
tumor-infiltrating lymphocytes and the clinical outcome of cancer
immunotherapy: A systematic review and meta-analysis.
EClinicalMedicine. 41:1011342021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu S, Lachapelle J, Leung S, Gao D,
Foulkes WD and Nielsen TO: CD8+ lymphocyte infiltration is an
independent favorable prognostic indicator in basal-like breast
cancer. Breast Cancer Res. 14:R482012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin
Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baker K, Lachapelle J, Zlobec I, Bismar
TA, Terracciano L and Foulkes WD: Prognostic significance of CD8+ T
lymphocytes in breast cancer depends upon both oestrogen receptor
status and histological grade. Histopathology. 58:1107–1116.
2011.PubMed/NCBI
|
|
14
|
Liu F, Lang R, Zhao J, Zhang X, Pringle
GA, Fan Y, Yin D, Gu F, Yao Z and Fu L: CD8(+) cytotoxic T cell and
FOXP3(+) regulatory T cell infiltration in relation to breast
cancer survival and molecular subtypes. Breast Cancer Res Treat.
130:645–655. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Denkert C, Loibl S, Noske A, Roller M,
Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R,
Hanusch C, et al: Tumor-associated lymphocytes as an independent
predictor of response to neoadjuvant chemotherapy in breast cancer.
J Clin Oncol. 28:105–113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al:
Prognostic and predictive value of tumor-infiltrating lymphocytes
in a phase III randomized adjuvant breast cancer trial in
node-positive breast cancer comparing the addition of docetaxel to
doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin
Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group, : Preferred reporting items for systematic
reviews and meta-analyses: The PRISMA statement. Ann Intern Med.
151:264–269. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Margulis AV, Pladevall M, Riera-Guardia N,
Varas-Lorenzo C, Hazell L, Berkman ND, Viswanathan M and
Perez-Gutthann S: Quality assessment of observational studies in a
drug-safety systematic review, comparison of two tools: The
newcastle-ottawa scale and the RTI item bank. Clin Epidemiol.
6:359–368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
|
|
20
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials revisited. Contemp Clin Trials. 45:139–145.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Borenstein M, Hedges LV, Higgins JP and
Rothstein HR: A basic introduction to fixed-effect and
random-effects models for meta-analysis. Res Synth Methods.
1:97–111. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
DerSimonian R and Kacker R: Random-effects
model for meta-analysis of clinical trials: An update. Contemp Clin
Trials. 28:105–114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Riley RD, Higgins JP and Deeks JJ:
Interpretation of random effects meta-analyses. BMJ. 342:d5492011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma C, Zhang Q, Ye J, Wang F, Zhang Y,
Wevers E, Schwartz T, Hunborg P, Varvares MA, Hoft DF, et al:
Tumor-infiltrating γδ T lymphocytes predict clinical outcome in
human breast cancer. J Immunol. 189:5029–5036. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mohammed ZM, Going JJ, Edwards J,
Elsberger B and McMillan DC: The relationship between lymphocyte
subsets and clinico-pathological determinants of survival in
patients with primary operable invasive ductal breast cancer. Br J
Cancer. 109:1676–1684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim ST, Jeong H, Woo OH, Seo JH, Kim A,
Lee ES, Shin SW, Kim YH, Kim JS and Park KH: Tumor-infiltrating
lymphocytes, tumor characteristics, and recurrence in patients with
early breast cancer. Am J Clin Oncol. 36:224–231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun S, Fei X, Mao Y, Wang X, Garfield DH,
Huang O, Wang J, Yuan F, Sun L, Yu Q, et al: PD-1(+) immune cell
infiltration inversely correlates with survival of operable breast
cancer patients. Cancer Immunol Immunother. 63:395–406. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu
X, Miao X and Tang Z: Intratumoral CD8(+) cytotoxic lymphocyte is a
favorable prognostic marker in node-negative breast cancer. PLoS
One. 9:e954752014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ali HR, Provenzano E, Dawson SJ, Blows FM,
Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, et al:
Association between CD8+ T-cell infiltration and breast cancer
survival in 12,439 patients. Ann Oncol. 25:1536–1543. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chung YR, Kim HJ, Jang MH and Park SY:
Prognostic value of tumor infiltrating lymphocyte subsets in breast
cancer depends on hormone receptor status. Breast Cancer Res Treat.
161:409–420. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu S, Chen B, Burugu S, Leung S, Gao D,
Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA and Nielsen TO:
Role of cytotoxic tumor-infiltrating lymphocytes in predicting
outcomes in metastatic HER2-positive breast cancer: A secondary
analysis of a randomized clinical trial. JAMA Oncol. 3:e1720852017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Papaioannou E, Sakellakis M, Melachrinou
M, Tzoracoleftherakis E, Kalofonos H and Kourea E: A Standardized
evaluation method for FOXP3+ tregs and CD8+ T-cells in breast
carcinoma: Association with breast carcinoma subtypes, stage and
prognosis. Anticancer Res. 39:1217–1232. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Groot AF, Blok EJ, Charehbili A, Engels
CC, Smit V, Dekker-Ensink NG, Putter H, Meershoek-Klein Kranenbarg
E, van de Velde CJ, Liefers GJ, et al: Strong CD8+ lymphocyte
infiltration in combination with expression of HLA class I is
associated with better tumor control in breast cancer patients
treated with neoadjuvant chemotherapy. Breast Cancer Res Treat.
175:605–615. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Catacchio I, Silvestris N, Scarpi E,
Schirosi L, Scattone A and Mangia A: Intratumoral, rather than
stromal, CD8+ T cells could be a potential negative prognostic
marker in invasive breast cancer patients. Transl Oncol.
12:585–595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Galon J and Bruni D: Approaches to treat
immune hot, altered and cold tumours with combination
immunotherapies. Nat Rev Drug Discov. 18:197–218. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van der Woude LL, Gorris MA, Halilovic A,
Figdor CG and de Vries IJ: Migrating into the tumor: A roadmap for
T cells. Trends Cancer. 3:797–808. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Berke G: The binding and lysis of target
cells by cytotoxic lymphocytes: Molecular and cellular aspects.
Annu Rev Immunol. 12:735–773. 1994. View Article : Google Scholar : PubMed/NCBI
|
